Verastem, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.0M
Doctors Paid
1,636
Transactions
5,182
2020 Total
$2.1M
Payment Breakdown by Category
Research$4.3M (72.0%)
Consulting$922,779 (15.4%)
Travel$106,015 (1.8%)
Food & Beverage$77,596 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.3M | 1,712 | 72.0% |
| Consulting Fee | $922,779 | 173 | 15.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $536,138 | 144 | 9.0% |
| Travel and Lodging | $106,015 | 412 | 1.8% |
| Food and Beverage | $77,596 | 2,717 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $27,353 | 23 | 0.5% |
| Grant | $5,000 | 1 | 0.1% |
Payments by Type
Research
$4.3M
1,712 transactions
General
$1.7M
3,470 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | $613,110 | 1 | 286 |
| VS-0145-225 | $567,145 | 2 | 278 |
| The Combination of Duvelisib, a PI3K?,? Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts | $334,667 | 0 | 1 |
| VS-0145-229 | $322,277 | 0 | 216 |
| A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | $278,167 | 0 | 108 |
| IST-145-06 | $253,431 | 0 | 24 |
| A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study | $239,672 | 0 | 367 |
| Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | $222,815 | 0 | 47 |
| IST-145-015 | $135,953 | 0 | 2 |
| 18-089 A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome | $122,400 | 0 | 3 |
| Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsVS-6063-203 | $111,073 | 0 | 9 |
| IPI-145 | $107,725 | 0 | 2 |
| OSU-18173 | $93,919 | 0 | 1 |
| GCNCR1029 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | $84,066 | 0 | 1 |
| 145-23 (Rollover) | $66,182 | 0 | 16 |
| A Pre-Clinical In Vitro and In Vivo Study of the Inhibitor of Phosphoinositide-3-Kinase (PI3K)-Delta and -Gamma Duvelisib to Overcome Therapeutically Resistant MCL | $65,800 | 0 | 1 |
| VS-0145-130 | $65,547 | 0 | 2 |
| A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With DuvelisibIPI-145-23 | $62,099 | 0 | 48 |
| BTP-114-101 IN ADVANCED SOLID TUMORS | $59,267 | 0 | 1 |
| A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) | $56,355 | 4 | 55 |
| VRSTM - Duvelisib | $50,000 | 0 | 2 |
| Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO) | $44,081 | 0 | 11 |
| Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO trial | $42,308 | 0 | 1 |
| IST-145-005 | $34,432 | 0 | 6 |
| IST-145-15 | $32,080 | 0 | 24 |
| IPI-145-06 | $29,824 | 3 | 47 |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) | $21,919 | 0 | 68 |
| IST-145-019 | $19,550 | 0 | 1 |
| IPI-145-12 | $18,837 | 0 | 5 |
| A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | $18,129 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Unknown Provider | — | — | $221,325 | $0 |
| Joanna Haas, M.d, M.D | Internal Medicine | Cambridge, MA | $205,520 | $0 |
| Dr. Asad Dean, Md, MD | Medical Oncology | Fort Worth, TX | $85,133 | $0 |
| Steven Wong, Md, MD | Hematology & Oncology | Santa Monica, CA | $78,849 | $0 |
| Narendranath Epperla, Md, MD | Internal Medicine | Columbus, OH | $51,032 | $0 |
| Dr. Alan Tan, M.d, M.D | Hematology & Oncology | Nashville, TN | $38,624 | $0 |
| Carole Miller, Md, MD | Medical Oncology | Baltimore, MD | $30,248 | $0 |
| Kasra Karamlou, M.d, M.D | Hematology & Oncology | Sandusky, OH | $26,982 | $0 |
| Alexey Danilov, M.d, M.D | Internal Medicine | Duarte, CA | $20,971 | $0 |
| Perry Cook, M.d, M.D | Hematology & Oncology | Brooklyn, NY | $19,449 | $0 |
| Ryan Jacobs, Md, MD | Internal Medicine | Charlotte, NC | $18,600 | $0 |
| Imad Tabbara, M.d, M.D | Hematology & Oncology | Washington, DC | $17,531 | $0 |
| Dr. Julio Hajdenberg, Md, MD | Hematology & Oncology | Boston, MA | $16,521 | $0 |
| Dr. Christopher Maisel, Md, MD | Hematology & Oncology | Dallas, TX | $15,439 | $0 |
| Dr. Moshe Levy, Md, MD | Medical Oncology | Dallas, TX | $14,615 | $0 |
| Dr. Stephen Sherwin, M.d, M.D | Medical Oncology | San Francisco, CA | $13,614 | $0 |
| Dr. Andrei Shustov, Md, MD | Hematology & Oncology | Seattle, WA | $13,388 | $0 |
| John Pagel, Md Phd, MD PHD | Hematology & Oncology | Seattle, WA | $13,357 | $0 |
| Jeffrey Zwicker, M.d, M.D | Hematology & Oncology | New York, NY | $12,700 | $0 |
| Dr. Deepa Jagadeesh, M.d, M.D | Internal Medicine | Worcester, MA | $12,617 | $0 |
| Kapil Dhingra, Md, MD | Medical Oncology | New York, NY | $12,500 | $0 |
| Joseph Readling, Md, MD | Hematology & Oncology | Binghamton, NY | $12,285 | $0 |
| Edmund Waller, M.d, M.D | Hematology | Atlanta, GA | $11,845 | $0 |
| Matthew Davids, M.d, M.D | Hematology & Oncology | Boston, MA | $11,827 | $0 |
| Adolfo Diaz, Md, MD | Hospitalist | San Antonio, TX | $11,591 | $0 |
Ad
Top Products
- Copiktra $5.3M
- Defactinib $356,206
Associated Products (3)
- Copiktra $5.6M
- Defactinib $356,206
- VS-4718 $10,240
Payment Categories
- Food & Beverage $77,596
- Consulting $922,779
- Travel & Lodging $106,015
- Research $4.3M
About Verastem, Inc.
Verastem, Inc. has made $6.0M in payments to 1,636 healthcare providers, recorded across 5,182 transactions in the CMS Open Payments database. In 2020, the company paid $2.1M. The top product by payment volume is Copiktra ($5.3M).
Payments were distributed across 41 medical specialties. The top specialty by payment amount is Hematology & Oncology ($581,836 to 901 doctors).
Payment categories include: Food & Beverage ($77,596), Consulting ($922,779), Research ($4.3M), Travel & Lodging ($106,015).
Verastem, Inc. is associated with 3 products in the CMS Open Payments database.